Latest News - Sun Pharma

Wednesday, December 27, 2017 | Dry Eye, Sun Pharma

FDA Accepts Sun Pharma's NDA for OTX-101 to Treat Dry Eye Disease

Sun Pharmaceutical Industries announced that the FDA has accepted a new drug application (NDA) filed by its US-based wholly owned subsidiary for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%, a …

Read the full story

Wednesday, January 04, 2017 | Clinical Trials, Dry Eye, Sun Pharma

Sun Pharma Announces Positive Topline Results of Confirmatory Phase 3 Clinical Trial for Seciera for Treatment of Dry Eye

Sun Pharma announced successful phase 3 confirmatory clinical trial results for Seciera (cyclosporine A 0.09% ophthalmic solution) for the treatment of dry eye disease, according to a company news rel…

Read the full story

Monday, November 28, 2016 | Product Releases, Sun Pharma

Sun Pharma Launches First Branded Ophthalmic Product, BromSite, in US

Sun Pharma announced the launch of BromSite (bromfenac ophthalmic solution) 0.075% in the United States. A nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative infl…

Read the full story

Wednesday, October 26, 2016 | Acquisitions/Mergers, Sun Pharma

Sun Pharma to Acquire Ocular Technologies

Sun Pharmaceutical Industries announced that it is acquiring Ocular Technologies, Sarl (OTS), a portfolio company of private equity firm Auven Therapeutics. OTS owns exclusive worldwide rights to …

Read the full story

Monday, September 26, 2016 | Miscellaneous, Sun Pharma

Sun Pharma Hosting Symposium on Managing Ocular Pain and Inflammation after Cataract Surgery

Sun Pharma is hosting a symposium titled "Managing Ocular Pain and Inflammation After Cataract Surgery: Differentiating Among the Non-Steroidal Anti-Inflammatory Drugs" on Saturday, October …

Read the full story